Niagen Bioscience, Inc. NAGE
At closeNov 6, 2026, 7:25 PM EST
After hours · Nov 6, 7:25 PM ET
- YTD
- -67.45%
- 1 year
- -68.64%
- Market cap
- 163.94M
- Revenue (ttm)
- 107.92M
- Profit margin
- 13.07%
- EPS (ttm)
- 0.12
- Shares out
- 78.77M
- P/E ratio
- 17.25
- YTD return
- -67.45%
- 1-year return
- -68.64%
- Volume
- 601.51K
- Avg volume
- 508.62K
- Open
- 2.06
- Previous close
- 2.11
- Day's range
- 2.04 – 2.11
- 52-week range
- 2.07 – 7.18
- Beta
- 2.08
- Price target
- 14.90 (+619.8%)
- Earnings date
- Aug 6, 2025
3M -1.05 (-33.65%)
Key statistics
- Enterprise value
- 1.09B
- PEG ratio
- 0.00
- Price / sales
- 9.19
- Price / book
- 17.89
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 37.60%
- Free cash flow
- 15.43M
- Total cash
- 55.46M
- Total debt
- 3.52M
- Return on equity
- 33.47%
- Short % of float
- 6.33%
- 50-day average
- 10.88
- 200-day average
- 7.00
Analyst view
- Target (low)
- 9.60
- Target (mean)
- 14.90
- Target (high)
- 23.00
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 6, 2025
Expected Aug 6, 2025. Consensus EPS estimate 0.00667.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 6, 2025 | Jun 1, 2025 | 0.02 | — | — | — |
| May 7, 2025 | Mar 1, 2025 | 0.02 | 0.04 | +0.02 | +100.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 10, 2025 | Canaccord Genuity | main | Buy | Buy |
| Jun 6, 2025 | Roth Capital | main | Buy | Buy |
| May 27, 2025 | Canaccord Genuity | init | — | Buy |
| Apr 8, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 31, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 17, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- niagenbioscience.com
News
Freedom Broker Maintains Buy on Niagen Bioscience, Lowers Price Target to $6
Canaccord Genuity Maintains Buy on Niagen Bioscience, Lowers Price Target to $7
Niagen Bioscience, Inc. (NAGE) Q3 2026 Earnings Call Transcript
Niagen Bioscience (NAGE) Reports Q3 Loss, Lags Revenue Estimates
Niagen Bioscience Q3 2026 Earnings Call Transcript Niagen Bioscience Raises FY2026 Sales Guidance from $138.982M-$145.299M to $145.299M-$151.616M vs $130.410M Est
Niagen Bioscience Q3 EPS $(0.01) Misses $0.02 Estimate, Sales $27.192M Miss $32.062M Estimate
Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results Canaccord Genuity Maintains Buy on Niagen Bioscience, Lowers Price Target to $9
Niagen Bioscience Enters Start-Up Agreement With Mass General Brigham To Plan The Largest And Most Comprehensive Clinical Trial Of Niagen To Date
Your note
Sign in to keep a note on NAGE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHAMPION RIVER VENTURES, LTD. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 5, 2023 | 0 |
| CHAU HOI SHUEN SOLINA HOLLY | Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 19, 2024 | 0 |
| FRIED ROBERT N. | Chief Executive Officer | Conversion of Exercise of derivative security | Apr 8, 2025 | 1,646,730 |
| GERBER BRIANNA | Chief Financial Officer | Purchase | Nov 30, 2023 | 28,674 |
| JAKSCH FRANK LOUIS JR | Director | Sale | Dec 12, 2024 | 2,319,230 |
| LI KA SHING | Beneficial Owner of more than 10% of a Class of Security | Sale | Aug 19, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 4.59% | 3,617,071 | 45.56M | Mar 30, 2025 |
| Vanguard Group Inc | 4.49% | 3,540,663 | 44.59M | Mar 30, 2025 |
| Tieton Capital Management, LLC | 2.52% | 1,986,040 | 25.01M | Mar 30, 2025 |
| Shaw D.E. & Co., Inc. | 1.63% | 1,283,790 | 16.17M | Mar 30, 2025 |
| Geode Capital Management, LLC | 1.50% | 1,179,217 | 14.85M | Mar 30, 2025 |
| Arrowstreet Capital, Limited Partnership | 1.26% | 989,873 | 12.47M | Mar 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.70% | 2,123,415 | 26.74M | Mar 30, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 1.59% | 1,252,089 | 15.77M | Apr 29, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.04% | 819,376 | 10.32M | Mar 30, 2025 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.64% | 500,412 | 6.30M | Apr 29, 2025 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.56% | 442,769 | 5.58M | Apr 29, 2025 |
| Invesco Exch-Trd Fd. TRT II-Invesco Dorsey Wright SmallCap Momentum ET | 0.41% | 325,635 | 4.10M | Apr 29, 2025 |
